Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Thymalfasin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6 Hematologic Neoplasms 2 Colorectal Neoplasms 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Neoplasms 1 Melanoma 1 MCRC 1 Lymphopenia 1 Locally Advanced Rectal Cancer 1 Esophageal Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

pembrolizumab 150 Gemcitabine 135 Paclitaxel 128 Carboplatin 118 Bevacizumab 110 Surveys and Questionnaires 97 Docetaxel 95 Cisplatin 94 Cyclophosphamide 93 Exercise 89 Blood Specimen Collection 85 Nivolumab 82 Fluorouracil 75 Capecitabine 73 Dexamethasone 70 Radiotherapy 69 Irinotecan 62 Standard of Care 59 Pemetrexed 59 Oxaliplatin 57 Leucovorin 54 Drug Therapy 54 Cetuximab 48 Erlotinib Hydrochloride 46 atezolizumab 44 Sorafenib 44 Interviews as Topic 41 Doxorubicin 41 Ipilimumab 38 Magnetic Resonance Spectroscopy 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05790447 2023-03-30

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Unknown

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡